Anika Therapeutics, Inc.ANIKNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank54
3Y CAGR-40.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-40.3%/yr
vs +138.7%/yr prior
Acceleration
-179.0pp
Decelerating
Percentile
P54
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 1.77% |
| Q3 2025 | -2.94% |
| Q2 2025 | -5.24% |
| Q1 2025 | 363.93% |
| Q4 2024 | -125.59% |
| Q3 2024 | 22.38% |
| Q2 2024 | -27.45% |
| Q1 2024 | 5.86% |
| Q4 2023 | -18.09% |
| Q3 2023 | 4.80% |
| Q2 2023 | -12.25% |
| Q1 2023 | 17.12% |
| Q4 2022 | 8.33% |
| Q3 2022 | 0.04% |
| Q2 2022 | 10.77% |
| Q1 2022 | -6.02% |
| Q4 2021 | 16.75% |
| Q3 2021 | -2.72% |
| Q2 2021 | -1.02% |
| Q1 2021 | 19.74% |
| Q4 2020 | -4.55% |
| Q3 2020 | 9.30% |
| Q2 2020 | 0.82% |
| Q1 2020 | 17.93% |
| Q4 2019 | 62.32% |
| Q3 2019 | 0.49% |
| Q2 2019 | -2.22% |
| Q1 2019 | 25.18% |
| Q4 2018 | 7.53% |
| Q3 2018 | -11.17% |
| Q2 2018 | -60.12% |
| Q1 2018 | 140.94% |
| Q4 2017 | 38.46% |
| Q3 2017 | -3.00% |
| Q2 2017 | -1.87% |
| Q1 2017 | -7.67% |
| Q4 2016 | 28.22% |
| Q3 2016 | 0.59% |
| Q2 2016 | 6.64% |
| Q1 2016 | -11.80% |